This series features essays by Dr. Kenneth Serbin, Professor of History, originally posted on his blog, At Risk for Huntington's Disease."
Huntington's Disease (HD) is a genetically caused brain disorder that causes uncontrollable bodily movements and robs people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
Blog Posts from 2019
‘We can now fear Huntington’s disease less’: reflections on the 14th Therapeutics Conference, Kenneth P. Serbin
CHDI’s chief scientist: ‘Not a time for the Huntington's community to rest its laurels', Kenneth P. Serbin
Continued progress, but also caution, in the fight against Huntington's disease, Kenneth P. Serbin
Hacking humans, upgrading Homo sapiens: the role of the Huntington's disease community and the consequences for life, Kenneth P. Serbin
A friend of the Huntington’s community receives award for HD article in influential Brazilian magazine, Kenneth P. Serbin
Blog Posts from 2018
Roche announces U.S., Canada sites for Phase 3 clinical trial of Huntington's disease drug, Kenneth P. Serbin
Building solidarity in disease communities’ quest for better care and treatments: a conversation with a young tennis award-winner, Kenneth P. Serbin
This Thanksgiving, appreciating stable health and new plans for Huntington's disease advocacy, Kenneth P. Serbin
Roche announces first sites for key Huntington’s disease observational study, Kenneth P. Serbin
Unpacking GENERATION HD1, the Roche Phase 3 Huntington's disease clinical trial, Kenneth P. Serbin
Roche Phase 3 clinical trial for Huntington’s disease gene-slicing drug to enroll volunteers in early 2019, Kenneth P. Serbin
In Harriet’s tragic death, the vulnerability caused by Huntington's disease – but also the story of a beautiful soul, Kenneth P. Serbin
Free from the threat of Huntington’s disease, our 'miracle baby' turns 18, Kenneth P. Serbin
New Ionis data show positive trends in clinical measures of Huntington's disease drug trial volunteers, Kenneth P. Serbin
Nora Guthrie: we’re all ‘hoping machines’ in the fight against Huntington's disease, Kenneth P. Serbin
Roche gears up for pivotal Phase 3 Huntington’s disease gene-slicing clinical trial, Kenneth P. Serbin
In chronicling the quest to cure Huntington’s disease, a whirlwind of emotions, Kenneth P. Serbin
The best news for the Huntington's disease community since the discovery of the gene: Ionis trial data revealed, Roche confirms jump to Phase 3, Kenneth P. Serbin
Overflow audience at 13th annual Huntington's Disease Therapeutics Conference, Kenneth P. Serbin
CHDI's 13th conference promises some good news for the Huntington's disease community, Kenneth P. Serbin
Faith in each other: sticking together through the challenges of Huntington's disease, Kenneth P. Serbin
Blog Posts from 2017
Ionis scientists provide initial assessment of successful Phase 1/2a Huntington's disease trial and discuss next steps, Kenneth P. Serbin
Ionis drug successfully reduces toxic Huntington’s disease protein, paving way for Phase 2 trial of effect on patients, Kenneth P. Serbin
A time for hope: HDSA’s 50th anniversary, a record-setting gala, and the impending release of highly anticipated clinical trial results, Kenneth P. Serbin
Advocacy in the workplace: raising awareness about Huntington's disease and brain health, Kenneth P. Serbin